With 2025 right around the corner, we're incredibly excited to be heading to San Francisco in January. The Artax team will be there in force, and we are looking forward to a busy schedule catching up with our biotech and pharma friends and colleagues. Please ping Maria Nichol, CBO, to set up a meeting if you'd like to talk to us about life, science and Nck modulation.
Artax Biopharma Inc
Biotechnology Research
Cambridge, MA 1,937 followers
Developing oral first-in-class Nck blockers for the treatment of T cell mediated autoimmune diseases
About us
Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T cell activation. Specific control over T cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.
- Website
-
http://www.artaxbiopharma.com
External link for Artax Biopharma Inc
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Cambridge, MA
- Type
- Public Company
- Founded
- 2013
Locations
-
Get directions
One Broadway
Cambridge, MA, US
Employees at Artax Biopharma Inc
Updates
-
The T cell receptor (or TCR) is central to healthy T cell function and a regulated immune system. When the immune system malfunctions and the TCR becomes dysregulated, T cells behave abnormally, attacking a patient’s own tissues and organs, resulting in autoimmune diseases. Nck is an adaptor protein which plays a direct role in T cell mediated diseases. Nck directly amplifies TCR responses and reduces the dysregulated TCR signaling which contributes to T cell mediated diseases. Artax Biopharma is developing first-in-class, oral small molecules that inhibit Nck binding to the TCR. Through this novel mechanism, Artax’s Nck inhibitors selectively modulate Nck’s amplification of the TCR, resulting in a lower T cell activation and less T cell response and allowing patients to receive treatment while avoiding the risks that come with immunosuppression. #autoimmunediseases #Nck #immunotherapy
-
While we wait for the data in psoriasis patients with our lead program AX-158, Artax CSO Dr. Christopher VanDeusen wanted to share some thoughts on what's next for AX-158.
-
It's been a week since we got back from #ACR24 where Scott Batty and Christopher VanDeusen had the opportunity to present on TCR-Nck modulators and AX-158. For all those interested in Artax Biopharma's posters at #ACR24, see our website: https://lnkd.in/e-Z5euHY
-
-
Thanks to The Chartered Institute of Patent Attorneys for hosting our own Maria Nichol at their #LifeSciences2024 session!
Rounding up CIPA's #LifeSciences2024 morning sessions! CIPA's Life Sciences Conference 2024 is taking place at the splendid De Vere Tortworth Court Hotel near Bristol. Marion Rees opened the day by congratulating long-serving Life Sciences Committee chair Simon Wright on his recent election as CIPA President for 2026. Simon chaired the first session of the day, where Jasper Clube (SNIPR Biome - A CRISPR Company), Maria Nichol (Artax Biopharma Inc), and Mathilda Davidson (Gowling WLG) shared their wealth of experience on ‘Preparing for and Surviving IP Transactions’. The second session of the morning left delegates under the capable guidance of cognitive neuroscientist Dr. Ula Cartwright-Finch (Cortex Capital Limited). Ula’s lively interactive session looked at how to ‘Master Advanced Negotiation Strategies, Fast!’ Attorneys identified if they had a competitive, collaborative, accommodating, or compromising negotiating style. As well as some tips on how to identify and deal with these styles. There were also a few lessons on awakening the inner Jedi to identify what people are thinking and feeling. The morning was broken with a refreshment break and ended with an informal lunch.
-
-
Our own Dr. Christopher VanDeusen, CSO of Artax, will be presenting at #ACR24 today from 10:30 AM -12:30 PM! Learn more about the promise of TCR-Nck Modulators for the treatment of autoimmune diseases.
-
-
Dr. Scott Batty, CMO of Artax, will be presenting on the tolerability and pharmacokinetics of the T cell receptor signal modulator at #ACR24 from 10:30 AM - 12:30 PM today. Come see us!
-
-
We're here at #ACR24! Come find us to chat about what Artax has coming in the next few months.
Don’t let the FOMO hit! With only 10 days until ACR Convergence 2024 begins, you still have time to join 10,000+ rheumatology professionals from across the globe in Washington D.C., November 14-19. ⏰ Not yet registered? No problem! Choose to attend in person or register now to secure on-demand content that’s viewable until October 31, 2025, to claim CME and ABIM/ABP MOC. Only a few days left to purchase on-demand access to this year’s scientific content! 📅 DON’T MISS OUT → https://acr.tw/44pY0G8 #ACR24
-
-
At Artax Biopharma, we are developing first-in-class Nck modulators to treat T cell mediated autoimmune disease such as #psoriasis, #atopicdermatitis, and more. We're excited by the progress we've been making in the development of our first novel mechanism, AX-158, as we rapidly approach results from our phase 2 trials for psoriasis treatment with first results expected in December 2024. We are simultaneously developing additional Nck modulator candidates for #autoimmunediseases with AX-194 undergoing preclinical testing to enter Phase 1 trials. Learn more about our candidate pipeline here: https://lnkd.in/eqq3eSTK #clinincaltrials #immunology
-